Ari Bousbib

Ari Bousbib orchestrated the 2016 merger of IMS Health (the world's largest healthcare data company) and Quintiles (the world's largest contract research organization) to create IQVIA — a unique combination of comprehensive healthcare data, advanced analytics, and clinical trial execution capabilities. As chairman and CEO, he has built IQVIA into the essential infrastructure partner for the pharmaceutical industry, connecting drug development with commercial operations through a proprietary data asset covering billions of anonymized patient records. IQVIA's competitive advantage lies in its data moat: the company processes prescription data from over 90% of US pharmacies, medical claims from hundreds of millions of patients, and electronic health records from healthcare systems worldwide. This data asset powers both IQVIA's Technology & Analytics Solutions segment (which helps pharma companies optimize commercial strategies, identify patients for clinical trials, and forecast drug demand) and its Research & Development Solutions segment (which runs clinical trials for pharma companies). Bousbib's execution on clinical trial bookings growth, technology platform adoption, and the integration of AI and machine learning into IQVIA's data analytics capabilities are the primary drivers of the stock. The secular trend toward outsourced drug development (pharma companies increasingly relying on CROs like IQVIA rather than conducting trials in-house) provides a structural tailwind.